pg_pro_header_fact_folly

ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.

References:

  1. Mirena [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2008.
  2. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility—follow-up after participation in a randomized clinical trial. Contraception. 2007;75(2):88-92.
  3. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB; for the U.S. Collaborative Review of Sterilization Working Group. Poststerilization regret: findings from the United States collaborative review of sterilization. Obstet Gynecol. 1999;93(6):889-895.
  4. Mosher WD, Martinez GM, Chandra A, Abma HC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data. 2004;350:1-36.
  5. Association of Women's Health, Obstetric and Neonatal Nurses. Female OB/GYNs speak out about health practices. AWHONN Lifelines. 2004;8(1):14-18.